INDIANAPOLIS , Feb. 28, 2017 \/CNW\/ --Eli Lilly and Company (LLY) will highlight new Phase 3 data evaluating Taltz (ixekizumab) for the treatment of moderate-to-severe plaque psoriasis and active psoriatic arthritis at the 75th annual meeting of the American Academy of Dermatology (AAD), which will take place March 3-7, 2017 , in Orlando, Fla. <\/p>\n
Lilly will present 14 abstracts, including one oral late-breaker presentation highlighting head-to-head data on the efficacy and safety of Taltz compared to Stelara* (ustekinumab) for the treatment of moderate-to-severe plaque psoriasis at 24 weeks. <\/p>\n
\"As the world's largest dermatology meeting, the American Academy of Dermatology annual meeting is an opportunity to highlight new information and data to experts in the dermatologic disease field,\" said Dr. Lotus Mallbris, global brand development leader, Taltz, Eli Lilly and Company. \"Nearly one year after the approval of Taltz in the U.S. and Europe , we are proud to bring new data further demonstrating the efficacy and safety of Taltz to the American Academy of Dermatology annual meeting.\" <\/p>\n
Studies, as well as the times and locations of the data sessions, are highlighted below. <\/p>\n
Oral Late-Breaker Presentation <\/p>\n
Saturday, March 4 <\/p>\n
Poster Presentations <\/p>\n
Sunday, March 5 <\/p>\n<\/p>\n
Indications and UsageTaltz (ixekizumab) is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. <\/p>\n
IMPORTANT SAFETY INFORMATION <\/p>\n
CONTRAINDICATIONSTaltz is contraindicated in patients with a previous serious hypersensitivity reaction, such as anaphylaxis, to ixekizumab or to any of the excipients. <\/p>\n
WARNINGS AND PRECAUTIONSInfectionsTaltz may increase the risk of infection. The Taltz group had a higher rate of infections than the placebo group (27% vs. 23%). Serious infections have occurred. Instruct patients to seek medical advice if signs or symptoms of clinically important chronic or acute infection occur. If a serious infection develops, discontinue Taltz until the infection resolves. <\/p>\n
Pre-Treatment Evaluation for TuberculosisEvaluate patients for tuberculosis (TB) infection prior to initiating treatment with Taltz. Do not administer to patients with active TB infection. Initiate treatment of latent TB prior to administering Taltz. Patients receiving Taltz should be monitored closely for signs and symptoms of active TB during and after treatment. <\/p>\n
HypersensitivitySerious hypersensitivity reactions, including anaphylaxis, angioedema and urticaria, have been reported with Taltz. If a serious hypersensitivity reaction occurs, discontinue Taltz immediately and initiate appropriate therapy. <\/p>\n
Inflammatory Bowel DiseaseCrohn's disease and ulcerative colitis, including exacerbations, occurred at a greater frequency in the Taltz group (Crohn's disease 0.1%, ulcerative colitis 0.2%) than in the placebo group (0%) during clinical trials. During Taltz treatment, monitor patients for onset or exacerbations of inflammatory bowel disease. <\/p>\n
ImmunizationsPrior to initiating therapy with Taltz, consider completion of all age-appropriate immunizations according to current immunization guidelines. Live vaccines should not be given with Taltz. <\/p>\n
ADVERSE REACTIONSMost common adverse reactions (>1%) associated with Taltz treatment are injection site reactions, upper respiratory tract infections, nausea, and tinea infections. <\/p>\n
Please see accompanying Prescribing Information and Medication Guide. Please see Instructions for Use included with the device. <\/p>\n
IX HCP ISI 18JAN2017 <\/p>\n
About Taltz (ixekizumab)Taltz (ixekizumab) is an IgG4 monoclonal antibody that selectively binds with interleukin 17A (IL-17A) cytokine and inhibits its interaction with the IL-17 receptor. IL-17A is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. Taltz inhibits the release of pro-inflammatory cytokines and chemokines. <\/p>\n
About Moderate-to-Severe Plaque PsoriasisPsoriasis is a chronic, immune disease that affects the skin.1 It occurs when the immune system sends out faulty signals that speed up the growth cycle of skin cells.Psoriasis affects approximately 125 million people worldwide, approximately 20 percent of whom have moderate-to-severe plaque psoriasis.1,[2] Psoriasis can occur on any part of the body and is associated with other serious health conditions, such as diabetes and heart disease.1 The most common form of psoriasis, plaque psoriasis, appears as raised, red patches covered with a silvery white buildup of dead skin cells.1 <\/p>\n
Read More <\/p>\n
AboutEli Lillyand CompanyLilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us atwww.lilly.comandnewsroom.lilly.com\/social-channels. <\/p>\n
P-LLYThis press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about Taltz (ixekizumab) as a treatment for moderate-to-severe plaque psoriasis, and reflects Lilly's current belief. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of development and commercialization. Among other things, there can be no guarantee that Taltz will receive additional regulatory approvals or be commercially successful. For further discussion of these and other risks and uncertainties, see Lilly's most recent Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release. <\/p>\n
_____________________________ 1 Psoriasis media kit. National Psoriasis Foundation website. https:\/\/www.psoriasis.org\/sites\/default\/files\/for-media\/MediaKit.pdf<\/a>. Accessed February 23, 2017 . 2 Psoriasis. American Academy of Dermatology website. https:\/\/www.aad.org\/media-resources\/stats-and-facts\/conditions\/psoriasis<\/a>. Accessed February 23, 2017 . <\/p>\n Refer to: Jen Dial ; dial_jennifer_kay@lilly.com<\/a>; 317-220-1172 (Lilly Bio-Medicines) <\/p>\n * Lilly USA , LLC 2017. All rights reserved. Taltz is a registered trademark owned or licensed by Eli Lilly and Company, its subsidiaries or affiliates. Stelara is a registered trademark owned or licensed by Janssen Pharmaceutical Companies of Johnson & Johnson, its subsidiaries or affiliates. <\/p>\n<\/p>\n To view the original version on PR Newswire, visit:http:\/\/www.prnewswire.com\/news-releases\/lilly-to-present-new-data-for-taltz-ixekizumab-in-psoriasis-and-psoriatic-arthritis-at-the-american-academy-of-dermatology-aad-annual-meeting-300414834.html<\/a> <\/p>\n SOURCE Eli Lilly and Company <\/p>\n To view this news release in HTML formatting, please use the following URL: http:\/\/www.newswire.ca\/en\/releases\/archive\/February2017\/28\/c5919.html<\/a> <\/p>\n <\/p>\n Read the rest here: INDIANAPOLIS , Feb. Continue reading
\nLilly to Present New Data for Taltz (ixekizumab) in Psoriasis and Psoriatic Arthritis at the American Academy of ... - Yahoo Finance<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"